跳至主要内容
临床试验/CTRI/2025/07/091420
CTRI/2025/07/091420尚未招募Phase 3 4

Evaluation of efficacy and safety of Shadbindu Taila Marsha Nasya and Chitraka Haritaki Avaleha in Chronic Rhinosinusitis: A Randomized Controlled Multicenter Study

Central Council for Research in Ayurvedic Sciences2 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2025年8月5日最近更新:

试验速览

阶段
Phase 3 4
状态
尚未招募
入组人数
160
试验地点
2
主要终点
Primary Outcome: The change in terms of

研究概览

简要总结

The prevalence
of chronic rhinosinusitis (CRS) measured in epidemiologic studies is 5% to
12%. Chronic Rhinosinusitis is one of the important global health problems
defined as inflammation of the mucous membrane of the nose and paranasal
sinuses. Chronic rhinosinusitis refers to a condition that lasts at least 12
weeks, despite attempts to treat it, and causes at least two of the symptoms;
nasal congestion, mucus discharge from the nose or mucus that drips down the
back of the throat, facial pain, pressure, or fullness, a decreased sense of
smell. The proximity of the brain to the sinuses makes the most dangerous
complication of Chronic Rhinosinusitis, particularly involving the frontal
and sphenoid sinuses, infection of the brain by   the invasion of anaerobic   bacteria through the   bones  
or   blood vessels. Abscesses,
meningitis and other life-threatening conditions may result. In extreme
cases, the patient may experience mild personality changes, headaches,
altered consciousness, visual problems, seizures, coma and possibly death.
The treatment strategy for Chronic Rhinosinusitis mainly includes the use of
topical decongestants, saline nasal drops, nasal saline irrigations, nasal
steroids, antihistamines, antibiotics and in some cases surgical interventions.
Even though not a life-threatening condition it produces difficulty in
carrying out day to day activities and greatly affects the quality of life. Pinasa Roga is one such chronic disease which affects
the nose and nasal passages*. Pinasa* is due to vitiated Vata Kapha, withNasaavarodha (Nasal obstruction), Nasashosha (dryness of the
nose), Gandha agyana (abnormal perception of smell) as the
characteristic symptoms. The various etiological factors mentioned (faulty
life style & regimen) leads to Agnimandya and Aama which is
the main causative factor for the disease. Ayurveda being a life science advocated preventive and curative
measures for the treatment of various chronic
diseases. Earlier researches have
proved the effectiveness of Ayurvedic treatment in the management of Pinasa
Roga. Chitraka Haritaki Lehya is mentioned in Nasarogadhikara Chikitsa
in Chakradutta (58/31-33). Shadbindu Tailais medication described in *Bhaishajyaratnavali Siroroga chikitsa
Prakarana* for the management of almost all Urdhajatrugata Rogas (65/81- 83).
Total 160 patients (80 at each participating center) will be included in the
study. The observations and discussion will be
made according to statistical analysis on different clinical & objective parameters and scores of questionnaires (Chronic Rhinosinusitis
Questionnaire). This
study has been proposed to evaluate the efficacy and
safety of Administration of Shadbindu Taila Marsha Nasya and Chitraka Haritaki Avleha in Chronic Rhinosinusitis.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Patients between the age group of 18 to 60 years.
  • Patients suffering with Pinasa (Chronic Rhinosinusitis) who are fulfilling the diagnostic criteria based on American system of Academy (AAO-HNS) will be selected for the present study.
  • Twelve weeks or longer of two or more of the following signs and symptoms: Mucopurulent drainage (anterior, posterior or both), Nasal obstruction (congestion), Facial pain-pressure-fullness Decreased sense of smell (b).
  • AND inflammation is documented by one or more of the following findings: Purulent (not clear) mucus or edema in the middle meatus or anterior ethmoid region, Polyps in nasal cavity or the middle meatus, and/or Radiographic imaging showing inflammation of the paranasal sinuses
  • Willing to participate in study.

排除标准

  • Patients below 18 and above 60 years of age.
  • History of chronic nasal or upper respiratory tract symptoms or disorders other than Chronic Rhinosinusitis.
  • Patients who are on treatment with H1 antihistamine medication, non-steroidal analgesics, Leukotriene antagonists.
  • Cases of fungal sinusitis (On Non- Contrast CT-PNS; Hypoattenuating mucosal thickening, intranasal/ intrasinus soft tissue attenuation/ opacification, associated osseous erosions, hyperdense fungal hyphae within sinus).
  • Presence of secondary immune deficiency state: HIV, organ transplant, Malignancy, Treatment with corticosteroids.
  • Known cases of Hepatitis B and C positive.
  • Pregnancy & Lactation.
  • Patients suffering from chronic debilitating disease like tuberculosis, rheumatoid arthritis, Pulmonary Dysfunction (Bronchial Asthma and / or.

结局指标

主要结局

Primary Outcome: The change in terms of

时间窗: On base line, 56th day, 84th day

SNOT-22 score (Sino-Nasal Outcome Test)

时间窗: On base line, 56th day, 84th day

次要结局

  • The change in RSDI score (Rhinosinusitis Disability Index)(On base line 56th day 84th day)
  • Lund-Mackay scores of computed tomography (CT) scan of paranasal sinuses(On base line, 56th day)
  • Change in the laboratory safety parameters from baseline(baseline, 56TH Day)
  • Dependence on rescue medicines(On base line, 14th day, 28th day, 42th day, 56th day)
  • Incidence of treatment emergent adverse events(On base line, 14th day, 28th day, 42th day, 56th day)

研究者

申办方类型
Research institution
责任方
Principal Investigator
主要研究者

Dr Shweta Mata

Central Ayurveda Research Institute New Delhi

研究点 (2)

Loading locations...

相似试验